Class III Factory price SARS-CoV-2 Antigen Test Set Nasopharyngeal Swab Malaysia 1 test/box

Description

Viral antigen rapid test kit for the detection of SARS-CoV-2 in human oropharyngeal, nasal, and nasopharyngeal swabs. The test is a lateral flow assay with a colloidal gold reporter, giving results in ten minutes.

Antigen is generally detectable in upper respiratory specimens during the acute phase of infection. Rapid diagnosis of SARS-CoV-2 infection will help healthcare professionals to treat patients and control the disease more efficiently and effectively.

The new coronavirus antigen test kit is a lateral flow immunoassay for the qualitative detection of SARS-COV-2 antigen (nucleocapsid protein) in upper respiratory samples with nasal swabs or saliva during the acute phase of infection.

Date sheet

Advantages of Antigen Rapid Test

Although the development cycle of antigen detection is relatively long, its
1.Sensitivity and specificity are higher than antibody detection
2.The pathogen can be detected at the initial stage of infection
3.Short TAT and simple operation.
4.No professional technicians and equipment are required, and the test can be completed in 15 min.
5.Home use.
6.Personal test.

Details Images

Jiangsu iiLO Biotechnology Co., Ltd. is located in Xukou Town, Wuzhong District, Suzhou City, Jiangsu Province. Suzhou is 100 kilometers away from Shanghai and 200 kilometers away from Nanjing. It is in the center of the Yangtze River Delta Economic Belt. Our main business covers two major sudivisions: BioScience and BioMedicine, including scientific instruments and life science reagents research, medical equipments and diagnostic reagents. From R&D to production and the marketing promotion of products.
We have maintained good business relationship with more than 100 biotechnology companies and customers both domestic and abroad.Our key domestic account including Nanjing University, Wuhan Institute of Virology CAS, etc. And our answering product --disposable collectors (saliva) have been exported to Hong Kong, Southeast Asia, Australia and North America.